# Drug reduces risk of relapse with neuromyelitis optica

**URL:** https://archive.menshealtharchive.com/t/drug-reduces-risk-of-relapse-with-neuromyelitis-optica/2406
**Category:** Research Database
**Created:** [May 3, 2019, 6:19pm UTC](https://archive.menshealtharchive.com/t/drug-reduces-risk-of-relapse-with-neuromyelitis-optica/2406 "2019-05-03T18:19:48Z")
**Posts on this page:** 1
**Page:** 1

<div class="post-metadata">

### Author: ![Science\_Daily](https://yyz1.discourse-cdn.com/flex035/user_avatar/archive.menshealtharchive.com/science_daily/32/325_2.png) [@Science\_Daily](https://archive.menshealtharchive.com/u/Science_Daily)
#### Post date: [May 3, 2019, 6:19pm UTC](https://archive.menshealtharchive.com/t/drug-reduces-risk-of-relapse-with-neuromyelitis-optica/2406/1 "2019-05-03T18:19:49Z")

</div>

> **[Drug reduces risk of relapse with neuromyelitis optica](https://www.sciencedaily.com/releases/2019/05/190503100831.htm)**
>
> The drug eculizumab, a synthetic antibody that inhibits the inflammatory response, significantly reduced the risk of relapse with neuromyelitis optica spectrum disorder (NMOSD). This rare but severe autoimmune inflammatory disorder can cause...

  
The drug eculizumab, a synthetic antibody that inhibits the inflammatory response, significantly reduced the risk of relapse with neuromyelitis optica spectrum disorder (NMOSD). This rare but severe autoimmune inflammatory disorder can cause blindness, paralysis and death.